Accepted for/Published in: JMIR mHealth and uHealth
Date Submitted: Jul 2, 2023
Open Peer Review Period: Jun 24, 2023 - Aug 19, 2023
Date Accepted: Apr 30, 2024
(closed for review but you can still tweet)
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Effectiveness of a Multi-faceted mHealth Intervention on Adherence to Medication and Treatment Outcome Among Patients with Hypertension in a Lower-Middle-Income Country: A Randomized Controlled Trial
ABSTRACT
Background:
The high prevalence of uncontrolled hypertension in Pakistan is predominantly attributed to poor drug adherence. Mobile phone innovations are cheap, ubiquitous, and culturally acceptable tools for behavioral change. As more than 137 million populations in Pakistan use mobile phones, a suitable mobile health (mHealth) module can be a suitable and effective tool to overcome poor drug adherence.
Objective:
This study sought to determine whether a novel mobile health intervention was useful in enhancing adherence to antihypertensive therapy and treatment outcomes among patients with hypertension in a developing country.
Methods:
A parallel, single-blinded, superiority randomized controlled trial of six months duration recruited 439 hypertensive patients at a public hospital in Pakistan, with poor adherence to antihypertensive therapy and access to smartphones. An innovative multifaceted, mHealth intervention, “Multi-Aid-Package”, based on the Health Belief Model was developed for the intervention group. The novel module contained written, audio & visual reminders, infographics, video clips, educational content, and 24/7 individual support, while the control group only received standard care. The primary outcome was self-reported medication adherence measured using the Self-efficacy for Appropriate Medication Adherence Scale (SEAMS) and pill-counting. The secondary outcome was a systolic blood pressure (SBP) change. Both outcomes were evaluated at the baseline and 6 months. Technology acceptance feedback was also assessed at the end of the study.
Results:
Of 439 participants, 423 could complete the study. In the control group, 10 participants were lost to follow-up, while one withdrew his consent. In the intervention group, 6 participants were lost to follow-up. At six months post-intervention, the median SEAMS score was higher in the intervention group (32, IQR 11) compared to the controls (21, IQR 6), and the difference was statistically significant (P<0.001). Within the intervention group, there was also an improvement of 12.5 points between baseline and 6 months (P<0.001). By using the pill-counting method, there was an increase in adherent patients between the intervention and the control groups (difference of 81 patients, P<0.001), as well as within groups (difference of 83 patients; baseline vs 6 months, P<0.001). As for the SBP, between groups, there was a statistically significant difference in SBP of 7mmHg (P<0.001) at 6 months, while within groups, there was a reduction by 4mmHg (P<0.001) within the intervention group, but there was an increase by 3mmHg (P=0.314) in the controls. Overall, the number of patients with uncontrolled hypertension was reduced by 46 patients in the intervention group (baseline vs 6 months), but the controls remained unchanged. The Multi-Aid-Package received a 94.8% acceptability score.
Conclusions:
The novel “Multi-Aid-Package” is an effective mHealth module in enhancing adherence to medication and treatment outcomes among patients with hypertension in a developing country. Clinical Trial: Clinical Trials. gov. NCT04577157
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.